How to get Strattera fast in New York

If you’re exploring treatment options for ADHD, you’ve likely wondered whether you can access non-stimulant medications like Strattera through telehealth. The short answer is yes—and in many ways, it’s simpler than getting stimulant medications online. But the details matter, especially as federal and state regulations continue to evolve.

This guide walks you through everything you need to know about getting non-stimulant ADHD medication via telehealth in 2025, including current laws, state-by-state differences, who can prescribe, and what to expect during your virtual visit.

Understanding Non-Stimulant ADHD Medications

Non-stimulant medications offer an effective alternative for managing ADHD symptoms, particularly for patients who can’t tolerate stimulants or have concerns about controlled substances.

What Is Strattera (Atomoxetine)?

Strattera is the most commonly prescribed non-stimulant ADHD medication. Unlike Adderall or Ritalin, Strattera is not a controlled substance, which fundamentally changes how it can be prescribed via telehealth. The FDA approved atomoxetine for ADHD treatment in children (ages 6+), adolescents, and adults.

Key characteristics of Strattera:

• No DEA scheduling: Not classified as a controlled substance, meaning no federal restrictions on telehealth prescribing
• No abuse potential: Non-habit-forming with no risk of dependency
• Different mechanism: Works by increasing norepinephrine in the brain rather than dopamine
• Gradual effect: Takes 4-6 weeks to reach full therapeutic benefit (unlike stimulants that work within hours)
• Once-daily dosing: Convenient for many patients
• Can be prescribed with refills: Unlike Schedule II stimulants that require new prescriptions monthly

Other Non-Stimulant Options

Beyond Strattera, healthcare providers may consider:

• Guanfacine (Intuniv): Originally a blood pressure medication, now approved for ADHD
• Clonidine (Kapvay): Another blood pressure drug used off-label for ADHD symptoms
• Bupropion (Wellbutrin): An antidepressant sometimes prescribed off-label for ADHD
• Viloxazine (Qelbree): A newer non-stimulant FDA-approved for ADHD in 2021

All of these are non-controlled substances and follow similar telehealth prescribing rules as Strattera.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

The Legal Landscape: Can Doctors Prescribe Non-Stimulants via Telehealth?

Federal Regulations (DEA Rules)

Here’s where non-stimulant ADHD medications have a significant advantage: federal law does not restrict telehealth prescribing of non-controlled substances.

The Ryan Haight Act of 2008, which typically requires an in-person medical evaluation before prescribing controlled substances online, does not apply to Strattera or other non-stimulant ADHD medications. Since these drugs aren’t DEA-scheduled, providers can evaluate patients via video consultation and e-prescribe without any federal requirement for a prior in-person visit.

Important context about controlled substances: You may have heard about the DEA’s temporary COVID-era telehealth flexibilities for controlled substances (like Adderall). These rules, currently extended through December 31, 2025, allow prescribing of Schedule II-V controlled medications via telehealth without an initial in-person exam. However, this is a temporary waiver that doesn’t affect non-stimulants. Whether or not the DEA extends this flexibility into 2026, non-stimulant prescribing via telehealth remains unaffected because it was never restricted in the first place.

State-Level Variations

While federal law is clear, state regulations add another layer. The good news: no state outright prohibits telehealth treatment for ADHD with non-stimulant medications. However, some states have specific telehealth practice standards you should know about.

States with Minimal Restrictions

California, Illinois, Pennsylvania, and most states allow telehealth prescribing of non-controlled medications with no special requirements beyond standard medical practice. A comprehensive video evaluation establishes the provider-patient relationship necessary for prescribing.

States with Periodic In-Person Requirements

Alabama and New Hampshire have rules requiring periodic follow-up evaluations, though these primarily target controlled substance prescribing:

• Alabama: After four telehealth visits for the same condition, state law requires an in-person visit within 12 months. However, mental health services are exempt from this requirement, and ADHD treatment typically falls under mental health care. Still, Alabama remains one of the strictest states for telehealth.

• New Hampshire: As of August 2025, providers must conduct a follow-up evaluation at least annually when prescribing controlled medications via telemedicine. For non-controlled drugs like Strattera, standard telehealth rules apply with no mandatory in-person visits.

States with Controlled Substance Focus

New York, Florida, and Texas have stricter rules for controlled substances but don’t impose additional barriers for non-stimulants:

• New York: May 2025 regulations require an in-person evaluation before prescribing any controlled substance via telehealth. This doesn’t affect Strattera prescriptions.

• Florida: Generally prohibits telehealth prescribing of Schedule II stimulants except for psychiatric conditions (ADHD qualifies). For non-controlled medications, there are no special restrictions.

• Texas: Very telehealth-friendly for mental health care, with no in-person requirement for ADHD treatment. Texas restrictions primarily affect NP/PA prescribing authority for Schedule II drugs, not non-stimulants.

Who Can Prescribe Non-Stimulant ADHD Medications via Telehealth?

Physicians (MD/DO)

In all 50 states, licensed physicians can prescribe non-stimulant ADHD medications via telehealth, provided they:

• Are licensed in the state where the patient is located
• Conduct an appropriate evaluation via audio-video technology
• Follow standard medical care protocols
• Comply with state telehealth practice laws

At Klarity Health, board-certified psychiatrists and physicians licensed in your state conduct comprehensive video evaluations to diagnose ADHD and prescribe appropriate treatments, including non-stimulant medications when clinically indicated.

Nurse Practitioners (NPs) and Physician Assistants (PAs)

The ability of NPs and PAs to prescribe ADHD medications—including non-stimulants—varies significantly by state:

Independent Practice States (NPs can prescribe without physician oversight):

• California, New York, Illinois, New Hampshire, and about 25 other states grant NPs full practice authority after meeting experience requirements
• In these states, NPs can independently evaluate, diagnose, and prescribe both stimulant and non-stimulant ADHD medications

Collaborative Practice States (NPs/PAs need physician agreements):

• Florida, Pennsylvania, and many others require a collaborative agreement with a supervising physician
• NPs and PAs can still prescribe non-stimulant medications, but they work under physician oversight
• For non-controlled drugs like Strattera, this typically poses no barrier—the collaborative structure allows for appropriate prescribing

Restricted States (limited Schedule II authority for NPs/PAs):

• Texas: NPs and PAs cannot prescribe Schedule II stimulants in outpatient settings (only in hospitals or hospice care). However, they can freely prescribe non-stimulants like Strattera under their collaborative agreements.
• Georgia: State law prohibits NPs from prescribing Schedule II controlled substances even with physician delegation. Non-stimulants remain prescribable under collaboration.

The bottom line: In every state, qualified NPs and PAs can prescribe Strattera and other non-stimulant ADHD medications via telehealth, though the level of physician involvement varies. Klarity Health matches patients with appropriately licensed and credentialed providers based on state requirements.

What to Expect: The Telehealth ADHD Evaluation Process

Getting non-stimulant ADHD medication through telehealth isn’t as simple as filling out an online quiz. Legitimate providers follow rigorous diagnostic protocols to ensure safe, appropriate care.

Initial Consultation

Your first telehealth appointment will typically involve:

Comprehensive symptom assessment: Your provider will use DSM-5 diagnostic criteria, asking detailed questions about:

• Inattention symptoms (difficulty focusing, forgetfulness, disorganization)
• Hyperactivity/impulsivity symptoms (restlessness, interrupting, difficulty waiting)
• When symptoms started (ADHD symptoms must be present before age 12)
• How symptoms impact multiple settings (work, home, relationships, school)

Medical history review:

• Previous mental health diagnoses or treatment
• Current medications and supplements
• Medical conditions (heart problems, high blood pressure, glaucoma, liver issues)
• Family psychiatric history
• Substance use history

Functional impairment evaluation:

• How ADHD symptoms affect your daily life, work performance, relationships, and overall functioning
• Previous coping strategies and their effectiveness

Rating scales and questionnaires:

• Many providers use validated ADHD screening tools like the Adult ADHD Self-Report Scale (ASRS)
• You may be asked to have a family member or close friend provide collateral information

Documentation Requirements

To ensure an accurate diagnosis, providers may request:

• Past psychological or psychiatric evaluations
• Previous ADHD testing results
• School records or report cards (especially for young adults)
• Documentation of prior ADHD treatment or medication trials

Be prepared to provide thorough information. Since the provider can’t conduct a physical exam, they rely heavily on your reported history. Honest, detailed responses lead to better care.

Prescription and Treatment Plan

If your provider determines that ADHD treatment with a non-stimulant is appropriate, they’ll discuss:

Medication selection: Why Strattera or another non-stimulant might be the best choice for you

• Advantages: No controlled substance restrictions, no abuse potential, can help with anxiety symptoms
• Disadvantages: Delayed onset (4-6 weeks), may not be as immediately effective as stimulants for some patients

Dosing strategy:

• Starting dose (typically low to minimize side effects)
• Titration schedule (gradually increasing to therapeutic dose)
• Expected timeline for symptom improvement

Monitoring plan:

• Follow-up appointment schedule (usually 2-4 weeks after starting)
• What side effects to watch for (decreased appetite, nausea, insomnia, mood changes)
• When to contact the provider between appointments

Complementary treatments:

• Behavioral strategies and organizational skills training
• Therapy referrals (CBT can be highly effective for ADHD)
• Lifestyle modifications (sleep hygiene, exercise, nutrition)

E-Prescribing and Pharmacy

Your provider will send your Strattera prescription electronically to your preferred pharmacy. Since it’s not a controlled substance:

• Refills are allowed: Typically prescribed with multiple refills (up to 11 months)
• 90-day supplies available: For convenience and cost savings
• No special pharmacy requirements: Any licensed pharmacy can fill it
• Insurance coverage: Most plans cover non-stimulant ADHD medications; Klarity Health also offers transparent cash pricing if you’re paying out of pocket

Strattera vs. Stimulants: Understanding Your Options

Many patients wonder whether they should try a stimulant or non-stimulant first. Here’s how they compare:

Your provider will help determine which medication class is most appropriate based on your symptoms, medical history, and treatment preferences. Many patients start with stimulants due to faster results, but non-stimulants are an excellent first-line option for certain individuals.

Safety Considerations and Monitoring

While Strattera is generally safe and well-tolerated, responsible prescribing includes ongoing monitoring.

Side Effects to Watch For

Common side effects (usually mild and temporary):

• Upset stomach or nausea (often improves if taken with food)
• Decreased appetite
• Dry mouth
• Dizziness
• Fatigue or drowsiness
• Insomnia (less common than with stimulants)

Serious side effects requiring immediate medical attention:

• Suicidal thoughts: The FDA requires a black box warning about increased suicidal ideation in children and adolescents. Providers monitor mood closely, especially in the first few months.
• Liver problems: Rare cases of severe liver injury have been reported. Your provider may order baseline liver function tests.
• Cardiovascular effects: Increased heart rate or blood pressure. Patients with pre-existing heart conditions need careful evaluation.
• Severe allergic reactions: Rare but possible.

Ongoing Telehealth Monitoring

Your provider will schedule follow-up visits to:

• Assess symptom improvement
• Monitor for side effects
• Adjust dosage if needed
• Evaluate overall functioning and quality of life
• Check vital signs (you may be asked to monitor blood pressure at home)

Regular communication is essential. If you experience concerning symptoms between appointments, telehealth platforms typically offer messaging or nurse lines to address urgent concerns.

Who Should NOT Get ADHD Medication via Telehealth?

Telehealth works best for relatively stable patients. You may need in-person care if you have:

• Active severe mental health crises: Uncontrolled bipolar disorder, active suicidal ideation, acute psychosis
• Complex medical conditions: Severe uncontrolled heart disease, seizure disorders requiring specialized monitoring
• Substance use disorders: Active addiction requiring intensive treatment (though a history of substance use doesn’t automatically disqualify you—especially for non-stimulants)
• Need for physical examination: Certain symptoms that require hands-on assessment

Reputable telehealth providers will refer you to in-person specialists when appropriate. This isn’t about denying care—it’s about ensuring you get the right level of care for your situation.

Cost and Insurance Coverage

Insurance Coverage

Most health insurance plans cover Strattera and other non-stimulant ADHD medications, though coverage specifics vary:

• Generic atomoxetine is typically covered with lower copays
• Prior authorization may be required by some insurers
• Step therapy: Some plans require trying a stimulant first before approving a non-stimulant

Klarity Health accepts most major insurance plans, making ADHD treatment accessible and affordable. During your initial consultation, the team can verify your coverage and estimate costs.

Cash Pay Options

If you’re uninsured or prefer not to use insurance:

• Klarity Health offers transparent cash pricing for both consultations and medication management
• Generic atomoxetine is relatively affordable (often $30-80/month without insurance)
• 90-day supplies at discount pharmacies can reduce per-month costs
• GoodRx and similar discount programs can significantly lower prescription costs

Comparing Costs: Telehealth vs. In-Person

The convenience and time savings of telehealth add up, especially for ongoing medication management that requires regular check-ins.

Addressing Common Concerns and Misconceptions

‘Online ADHD prescriptions are too easy to get’

Reality: Legitimate telehealth providers follow the same diagnostic standards as in-person practices. Klarity Health providers conduct comprehensive evaluations using DSM-5 criteria, review medical history thoroughly, and won’t prescribe medications if clinically inappropriate.

The media coverage of questionable telehealth startups in 2022-2023 (like investigations into Cerebral and Done) led to industry-wide improvements. Reputable platforms responded by implementing stricter protocols, better clinician oversight, and enhanced patient safety measures.

‘Non-stimulants don’t really work’

Reality: While stimulants have higher response rates and work faster, non-stimulants are genuinely effective for many patients. Research shows that approximately 60-70% of patients respond well to Strattera.

Non-stimulants may actually be more effective for certain patients:

• Those with comorbid anxiety (stimulants can worsen anxiety)
• Patients with substance use concerns
• Individuals who experience intolerable stimulant side effects
• People who need consistent 24-hour symptom coverage

Additionally, because Strattera addresses underlying norepinephrine levels rather than providing a temporary boost, some patients experience more stable, sustainable improvement.

‘Telehealth doctors can’t prescribe ‘real’ ADHD medication’

Reality: Licensed telehealth providers have the same prescribing authority as in-person doctors. For non-controlled substances like Strattera, there are essentially no legal barriers. For controlled substances (stimulants), temporary federal rules currently allow telehealth prescribing, though this is subject to change after December 31, 2025.

‘My local pharmacy won’t fill a telehealth prescription’

Reality: Pharmacies routinely fill prescriptions from telehealth providers. E-prescriptions don’t indicate whether your visit was virtual or in-person.

That said, some pharmacies did increase scrutiny of stimulant prescriptions from certain online platforms in 2023 due to regulatory concerns. Using an established telehealth service and maintaining a relationship with one pharmacy helps ensure smooth prescription fills. Strattera prescriptions face virtually no special scrutiny since it’s not a controlled substance.

Tips for Successful Telehealth ADHD Treatment

Before Your First Appointment

1. Gather relevant documentation: Previous diagnoses, medication lists, school records if available
2. Write down your symptoms: When they occur, how they impact your life, how long you’ve experienced them
3. List questions and concerns: What you want to achieve with treatment, any worries about medication
4. Ensure good technology: Test your video connection, find a private, quiet space
5. Be honest about substance use: Your provider needs complete information to prescribe safely

During Treatment

1. Attend follow-up appointments: Don’t skip check-ins, even if you’re feeling better
2. Communicate openly: Report side effects promptly; discuss what’s working and what isn’t
3. Give medications adequate time: Strattera needs 4-6 weeks to reach full effect—don’t give up too soon
4. Track your symptoms: Keep notes on improvements, challenges, and side effects
5. Follow the treatment plan: Take medication as prescribed; don’t adjust doses without provider guidance

Maximizing Your Results

ADHD treatment works best when medication is combined with behavioral strategies:

• Consider therapy: Cognitive-behavioral therapy (CBT) specifically designed for ADHD can teach valuable skills
• Develop organizational systems: Use planners, apps, reminders to support executive function
• Optimize your environment: Minimize distractions, create routines, break tasks into manageable steps
• Prioritize sleep and exercise: Both significantly impact ADHD symptoms
• Build support networks: Connect with ADHD coaches, support groups, or online communities

Klarity Health providers can connect you with additional resources including therapy referrals and coaching services to support your ADHD management comprehensively.

What Happens if Regulations Change?

The landscape of telehealth ADHD treatment continues to evolve. Here’s what to know:

Current Status (December 2025)

• For non-stimulants (Strattera): No regulatory uncertainty—telehealth prescribing is fully legal and not subject to temporary waivers
• For stimulants: The DEA’s COVID-era flexibilities expire December 31, 2025. A fourth extension is anticipated, but not yet finalized.

Possible 2026 Scenarios

If the DEA extends telehealth flexibilities:

• Treatment continues as current for both stimulants and non-stimulants
• Possible new requirements (e.g., periodic in-person visits after a certain timeframe)

If the DEA waiver expires without replacement:

• Non-stimulant prescribing via telehealth continues unaffected
• Stimulant prescribing would revert to Ryan Haight Act requirements (initial in-person exam)
• Alternative options: Klarity Health could help coordinate in-person evaluations with local providers while continuing telehealth follow-up

If new permanent regulations are adopted:

• The DEA has proposed a ‘special registration’ pathway for telehealth controlled substance prescribing
• This could create permanent, structured telehealth access with appropriate safeguards

Staying Informed

Reputable telehealth providers monitor regulatory changes closely and communicate proactively with patients. If you’re a current patient, you’ll receive advance notice of any policy changes that affect your care, along with options for continuity of treatment.

Why Choose Klarity Health for ADHD Treatment?

Klarity Health makes getting ADHD care simple, affordable, and clinically excellent:

Provider Expertise: Board-certified psychiatrists and psychiatric nurse practitioners who specialize in ADHD across the lifespan

Appointment Availability: Meet with a provider within days, not months. Flexible scheduling including evenings and weekends.

Transparent Pricing: Clear costs upfront. We accept most major insurance plans and offer affordable cash-pay options.

Comprehensive Care: Not just prescriptions—our providers take time for thorough evaluations, medication management, and can coordinate with therapists for holistic treatment.

Convenient Medication Management: E-prescriptions sent to your preferred pharmacy. For non-stimulants like Strattera, we can prescribe 90-day supplies with refills for added convenience.

Privacy and Security: HIPAA-compliant platform with secure video consultations from the comfort of your home.

Ongoing Support: Regular follow-ups, easy messaging with your provider, and a care team available to answer questions.

Ready to Get Started?

If ADHD symptoms are impacting your life, you don’t need to wait months for an in-person appointment or navigate complicated regulatory uncertainty. Non-stimulant medications like Strattera can be safely and legally prescribed via telehealth, offering an accessible path to treatment.

Schedule your consultation with Klarity Health today. Our experienced providers will conduct a comprehensive evaluation, discuss all treatment options (including both stimulant and non-stimulant medications), and create a personalized care plan that works for your life.

Whether you’re newly considering ADHD treatment, looking for alternatives to stimulants, or seeking more convenient care, Klarity Health is here to help—with transparent pricing, fast appointment availability, and providers who truly listen.

References and Citations

1. ‘The Drug Enforcement Administration finalized a one-year extension for telehealth prescribing of controlled substances.’ FierceHealthcare, November 2024. Available at: www.fiercehealthcare.com

2. McDermott Will & Emery. ‘DEA Signals Extension of Telemedicine Flexibilities for Controlled Substance Prescribing for 2026.’ December 2025. Available at: www.mwe.com

3. Sheppard Mullin Richter & Hampton LLP. ‘Telehealth and In-Person Visits: Tracking Federal and State Updates to Pandemic-Era Telehealth Exceptions.’ National Law Review, August 15, 2025. Available at: www.sheppardhealthlaw.com

4. Medical News Today. ‘Is Strattera a controlled substance?’ Medically reviewed, January 14, 2025. Available at: www.medicalnewstoday.com

5. Center for Connected Health Policy. ‘Online Prescribing – State Telehealth Laws and Reimbursement Policies.’ Accessed November-December 2025. Available at: www.cchpca.org

This article was verified as of December 17, 2025. Regulations regarding telehealth and controlled substance prescribing continue to evolve. Always consult with a licensed healthcare provider about your specific situation and verify current state and federal requirements.

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment